Advanced Oncotherapy PLC Director Dealing (4259N)
October 25 2016 - 9:01AM
UK Regulatory
TIDMAVO
RNS Number : 4259N
Advanced Oncotherapy PLC
25 October 2016
25 October 2016
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Director Dealing
Advanced Oncotherapy (AIM: AVO), the developer of
next-generation proton therapy systems for cancer treatment,
announces that between 19 August 2016 and 16 September 2016 Lord
David Evans, a Non-Executive Director of the Company, disposed of
136,296 ordinary shares of 25 pence each in the Company ("Ordinary
Shares"), at a weighted average price of 121 pence per share.
Following these transactions, Lord Evans now holds 14,816
Ordinary Shares representing 0.12% of the issued share capital of
the Company.
Advanced Oncotherapy Plc www.avoplc.com
Dr. Michael Sinclair, Tel: +44 20 3617 8728
Executive Chairman & CEO
Nicolas Serandour, CFO
& COO
Stockdale Securities (Nomad
& Joint Broker)
Antonio Bossi / David Tel: +44 20 7601 6100
Coaten
Beaufort Securities (Joint
Broker)
Jon Belliss / Elliot Hance Tel: +44 20 7382 8300
Walbrook PR (Financial Tel: +44 20 7933 8780 or
PR & IR) avo@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 7980 541 893 /
Mob: +44 7876 741 001
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy with
protons that harnesses the best in modern technology. Advanced
Oncotherapy's team "ADAM", based in Geneva, focuses on the
development of a proprietary proton accelerator called Linac Image
Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the
energy levels achieved in legacy machines but in a unit that is a
quarter of the size and between a quarter and a fifth of the cost.
This compact configuration delivers proton beams in a way that
facilitates a greater precision and electronic control which is not
achievable with older technologies.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with an innovative
technology as well as better health outcomes and lower treatment
related side effects.
The Company has signed a purchase agreement with Sinophi
Healthcare Limited for one LIGHT proton therapy system to be
installed in a hospital in China and has further Letters of Intent
from other healthcare providers.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton therapy and actively
seeks working relationships with providers of these innovative
technologies. Through these relationships, the Company will remain
the prime provider of an innovative and cost-effective system for
particle therapy with protons.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBXBDGIUDBGLU
(END) Dow Jones Newswires
October 25, 2016 10:01 ET (14:01 GMT)
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2024 to May 2024
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From May 2023 to May 2024